Neuphoria Therapeutics Inc
Research Neuphoria Therapeutics Inc (NEUP) on Bullrun: market cap USD 20.76M, P/E 3.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNEUP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 20.76M
- P/E3.0
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 505.06K
- Free cash flow-USD 3.34M
Valuation Snapshot
latest market cap is USD 20.76M; P/E is 3.0.
Peer valuation comparison
Latest P/E is 3.03x versus a Healthcare sector median of 24.46x (87.6% below).
Latest P/E is 3.03x versus a United States median of 24.87x (87.8% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 15.65M | -USD 400.00K | n/a | n/a | -0.23 | USD 14.21M | USD 33.47K | USD 19.00M |
| FY2024 | USD 662.72K | -USD 15.49M | -USD 14.10M | n/a | -18.62 | USD 12.61M | USD 199.40K | USD 17.49M |
| FY2023 | n/a | -USD 21.38M | n/a | n/a | -0.02 | USD 12.10M | USD 1.07M | USD 22.01M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 20.76M | 3.0 | n/a | n/a |
| 2025 | 2025-12-31 | USD 20.86M | 29.8 | n/a | n/a |
| 2024 | 2024-12-31 | USD 5.59M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 26.08B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 75.52B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 197.22B | n/a | n/a | n/a |
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Neuphoria Therapeutics Inc's market cap?
Neuphoria Therapeutics Inc's market capitalization is USD 20.76M.
What is Neuphoria Therapeutics Inc's P/E ratio?
Neuphoria Therapeutics Inc's price-to-earnings (P/E) ratio is 3.0.
What does Neuphoria Therapeutics Inc do?
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer.